Second-generation antipsychotic use in children and adolescents: A six-month prospective cohort study in drug-naïve patients

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 53, Issue 11, 2014, Pages 1179-1190.e4

  Arango, Celso ^a   Giráldez, Miriam ^a   Merchán Naranjo, Jessica ^a   Baeza, Inmaculada ^b   Castro Fornieles, Josefina ^b   Alda, Jose Angel ^c   Martínez Cantarero, Carmen ^d   Moreno, Carmen ^a   De Andrés, Pilar ^a   Cuerda, Cristina ^a   De La Serna, Elena ^a   Correll, Christoph U ^e,f   Fraguas, David ^a   Parellada, Mara ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^e ZUCKER HILLSIDE HOSPITAL   (United States)

^f Hofstra North Shore Long Island Jewish School of Medicine   (United States)

Author keywords

Metabolic syndrome; Olanzapine; Quetiapine; Risperidone; Youth

Indexed keywords

GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADOLESCENT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISRUPTIVE BEHAVIOR; DRUG EFFECT; FEMALE; FOLLOW UP; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; MOOD DISORDER; MULTICENTER STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; WEIGHT CHANGE; WEIGHT GAIN; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; MENTAL DISORDERS; PRESCHOOL CHILD; PROGNOSIS; PROSPECTIVE STUDY; PSYCHOLOGY; RISK FACTOR;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; RISPERIDONE;

EID: 84927696136     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2014.08.009     Document Type: Article

References (40)

1. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring). 2008;16:2323-2330.
2. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
3. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47:9-20.
4. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765-1773.
5. Fraguas D, Correll CU, Merchan-Naranjo J, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. 2011;21:621-645.
6. Fraguas D, Merchan-Naranjo J, Laita P, et al. Metabolic and hormonal side effects in children and adolescents treated with secondgeneration antipsychotics. J Clin Psychiatry. 2008;69:1166-1175.
7. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420-1431.
8. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. Cardiovascular and Metabolic Risk in Outpatients with Schizophrenia Treated with Antipsychotics: results of the CLAMORS Study. Schizophr Res. 2007;90:162-173.
9. De Hert M, Detraux J, Van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8:114-126.
10. Straker D, Correll CU, Kramer-Ginsberg E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry. 2005;162:1217-1221.
11. Arango C, Robles O, Parellada M, et al. Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry. 2009;18:418-428.
12. Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2006;15:177-206.
13. Morrison JA, Friedman LA, Wang P, Glueck CJ. Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. J Pediatr. 2008;152:201-206.
14. Sinaiko AR, Donahue RP, Jacobs DR Jr, Prineas RJ. Relation of weight and rate of increase in weight during childhood and adolescence to body size, blood pressure, fasting insulin, and lipids in young adults. The Minneapolis Children's Blood Pressure Study. Circulation. 1999;99:1471-1476.
15. Bhargava SK, Sachdev HS, Fall CH, et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med. 2004;350:865-875.
16. Tirosh A, Shai I, Afek A, et al. Adolescent BMI trajectory and risk of diabetes versus coronary disease. N Engl J Med. 2011;364:1315-1325.
17. Juonala M, Raitakari M, Viikari J, Raitakari OT. Obesity in youth is not an independent predictor of carotid IMT in adulthood. The Cardiovascular Risk in Young Finns Study. Atherosclerosis. 2006;185:388-393.
18. Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA. 2003;290:2277-2283.
19. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63:679-685.
20. Olfson M, Blanco C, Liu SM, Wang S, Correll CU. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry. 2012;69:1247-1256.
21. Vitiello B, Correll C, Van Zwieten-Boot B, Zuddas A, Parellada M, Arango C. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19:629-635.
22. Zuddas A, Zanni R, Usala T. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol. 2011;21:600-620.
23. Agency for Healthcare Research and Quality (AHRQ). Comparative effectiveness of first and second generation antipsychotics in the pediatric and young adult populations. 2010. Available at: http://effectivehealthcare.ahrq.gov/ehc/products/147/453/Peds%20Anti psychotics%20Protocol%20Final.pdf. Accessed December 4, 2013.
24. Varley CK, McClellan J. Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. JAMA. 2009;302:1811-1812.
25. Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH. First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry. 2010;19:124-137.
26. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:771-791.
27. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555-576.
28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
30. Tapia Ceballos L, Lopez Siguero JP, Jurado Ortiz A. Prevalencia del síndrome metabólico y sus componentes en niños y adolescentes con obesidad. An Pediatr (Barc). 2007;67:352-361.
31. Sobradillo B, Aguirre A, Aresti U, Bilbao C, Fernández-Ramos C, Lizárraga A. Curvas y tablas de crecimiento: estudios longitudinal y transversal. Bilbao: Fundación Faustino Orbegozo Eizaguirre; 2004.
32. Dalmau Serra J, Alonso Franch M, Gomez Lopez L, Martinez Costa C, Sierra Salinas C. Obesidad infantil. Recomendaciones del Comité de Nutrición de la Asociación Española de Pediatría. Parte II. Diagnóstico. Comorbilidades. Tratamiento. An Pediatr (Barc). 2007;66:294-304.
33. Flodmark CE, Lissau I, Moreno LA, Pietrobelli A, Widhalm K. New insights into the field of children and adolescents' obesity: the European perspective. Int J Obes Relat Metab Disord. 2004;28:1189-1196.
34. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med. 2003;157:821-827.
35. Moreno C, Merchan-Naranjo J, Alvarez M, et al. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord. 2010;12:172-184.
36. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67:255-262.
37. Merchan-Naranjo J, Tapia C, Bailon C, et al. Secondary effects of antipsychotic treatment in naive or quasi-naive children and adolescents: design of a follow-up protocol and baseline results. Rev Psiquiatr Salud Ment. 2012;5:217-228.
38. Safer DJ. Age-grouped differences in adverse drug events from psychotropic medication. J Child Adolesc Psychopharmacol. 2011;21:299-309.
39. Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:60-70.
40. Seida JC, Schouten JR, Boylan K, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics. 2012;129:e771-e784.